Medical Research and Innovation : Innovation + Job News

Profectus BioSciences also received $2.75M in continued contract support from the Division of AIDS to develop its recombinant Vesicular Stomatitis Virus (rVSV) platform as an HIV vaccine. VSV is a negative-strand, non-segmented RNA virus from the order Mononegavirales that has been redesigned to enable delivery of vaccine immunogens. VSV is a particularly attractive candidate for this purpose because its genome can potentially host more than one foreign gene and it contains its own Profectus BioSciences is utilizing this technology along with its pDNA platforms to develop effective therapeutic vaccines against HCV, HPV, HSV, as well as HIV.

This funding is in addition to the $4.4M in grants announced earlier this week to support the Company's HIV prophylactic vaccine program.

Source: Profectus BioSciences
Writer: Walaika Haskins

Bmore Fiber, a group of business leaders and residents working to bring super high-speed broadband access to Baltimore, has won the $10,000 Gigabit Genius Award, created and funded by Philadelphia's startup and technology communities to encourage gigabit innovation worldwide. A panel of expert judges selected by Philadelphia's Division of Technology were instructed to choose the most promising projects from anywhere in the world.

The winning projects were chosen from among 20 finalists by a panel of expert judges drawn from Philadelphia's technology, civic, academic, and entrepreneurial leadership.

The projects were chosen for their potential to transform lives using ultra high-speed Internet connectivity known as gigabit. Gigabit technology would make the Internet up to 100 times faster than it is today, a difference in speed similar to the transition from dial-up modems to broadband Internet connections.

Bmore Fiber was awarded the bulk of the prize, $7,500, to begin developing teleradiology technology that will enable specialists to transmit and review radiology scans in real-time, making the experience identical whether the specialists are in the next room or the next continent.

"We are going to meet to consider our next steps. This is a big topic. One question is whether the funds should go to enabling the gigabit technology and then seek a path for the teleradiology work, or whether we should start work on the teleradiology project right away. In my mind the two are inextricably linked, so we'll have to see what makes sense," says David Troy, a Baltimore-based entrepreneur and spokesperson for Bmore Fiber.

The team will also start looking for partners from among Baltimore's robust technology and healthcare sectors.

"We have a broad range of volunteers here in the community, but we don't have anyone specifically lined up for the teleradiology project yet. Here in Baltimore, though, it would seem that with Hopkins and UMD medicine so strong here, we should not have trouble finding willing partners," says Troy.

The remainder of the prize, $2,500, was awarded to Israeli entrepreneur Daniel Dobroszklanka for a remote education project that would enable students anywhere in the world to participate in a world-class live classroom experience.

Source: Dave Troy, Bmore Fiber
Writer: Walaika Haskins

The University of Maryland, in partnership with the University of Maryland, Baltimore (UMB) and University of Maryland Baltimore County (UMBC), has received a $7.9 million federal grant to acquire a superconducting 950 MHz Nuclear Magnetic Resonance (NMR) magnet that will help researchers unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases.

The grant is among the largest of its kind ever awarded by the National Center for Research Resources (NCRR), part of the National Institutes of Health. The funds were made available through the American Recovery and Reinvestment Act of 2009.

The NMR is scheduled to be installed in November, 2011 at the University of Maryland School of Medicine in Baltimore. It will be shared equally among the three campuses and used by researchers throughout the Mid-Atlantic region. Only one other site in the United States currently has a 950 MHz NMR spectrometer, and the University of Maryland partnership will be the only academic institutions in the country to have this powerful technology.

David Fushman, professor of chemistry and biochemistry at the University of Maryland, is a co-director of the grant, and will lead the College Park team that includes several biochemists and cell biologists whose research will be enhanced by the new NMR spectrometer.

David J. Weber, professor of biochemistry and molecular biology at the University of Maryland School of Medicine and director of the NMR core facility there, and AIDS researcher Michael F. Summers, professor of chemistry and biochemistry at UMBC, are co-directors with Professor Fushman.

The eight-ton magnet produces a supercharged magnetic field that enables scientists to investigate the three-dimensional structure of biological molecules and study their interaction with the highest degree of resolution.

"This 950 Mhz NMR is optimal for studying large molecules," explains Fushman, an expert in protein structure and dynamics who is associated with the university's Center for Biomolecular Structure and Organization (CBSO). "This will allow us to move into studying larger protein complexes that include more than 1000 amino acids. We can begin to decipher interactions between proteins that we could not easily do before."

The 950 MHz NMR spectrometer will enable University of Maryland researchers to delve deeper into the molecular mechanisms of proteins and nucleic acids in the body and to provide the much needed fundamental information from which drug therapies and other medical treatments can be based. Researchers at the University of Maryland School of Medicine will utilize the technology in many areas of cancer research, including drug development, while UMBC researchers will focus on AIDS research.

Source: University of Maryland, Baltimore
Writer: Walaika Haskins

The Johns Hopkins Institute for Clinical and Translational Research (ICTR), in collaboration with Anne Arundel Health System (AAHS) and the Greater Baltimore Medical Center (GBMC), has established a new network of academic and community-based clinical researchers, the Johns Hopkins Clinical Research Network (JHCRN). The JHCRN, which will provide new opportunities for research collaborations, is designed to accelerate the transfer of new diagnostic, treatment, and disease-prevention advances from the research arena to patient care.

The JHCRN creates a bridge for research between Hopkins and community-based medical centers by linking physician-scientists and staff from the Johns Hopkins Medical Institutions with community-based medical centers in the region. The network, which will ultimately have additional member institutions, will serve several purposes, the most important of which is to make clinical trials available to patients who may not ordinarily have access to them.

"This strategy started four years ago when the newly ICTR wanted to expand its capacity for doing research and to take advantage of the potential collaboration of physicians both at GBMC and Anne Arundel who wanted to collaborate with us to do joint trials, but we didn't have a mechanism for at that time," says Dr. Charles Balch, Deputy Director for Clinical Trials and Outcomes Research, JH Institute for Clinical and Translational Research Director, Johns Hopkins Clinical Research Network.

"What's unique about it is that it's intended to facilitate collaborations of physicians in any specialty, although we've started initially in cancer because that's the most mature area of clinical trials in many facilities. We're moving quickly into other areas such as diabetes, heart disease, vascular disease and so forth," he continues.

The JHCRN directly addresses the many complexities of conducting multisite and multi-institutional trials by providing investigators with a larger patient pool and a seamless platform that uses common research protocols. The goal of the network is to speed the approval of new trials while ensuring careful oversight of patient safety. Rapid start-up and timely completion of research studies, aided by widespread access to the clinical trials, will make promising therapies available for patient use more quickly.

The network was established through an initial agreement with charter affiliate AAHS in early 2009. This early collaboration was instrumental in clearing many of the organizational and legal barriers to shared research, a process that continues with the inclusion of newer affiliate GBMC. The initial focus of the JHCRN will be on expanding cancer-related clinical trials (including medical, surgical, and radiation therapy aspects of cancer treatment) and diabetes and surgical studies. Future collaborations will include a wide range of research areas, including intensive care; cardiovascular, neuropsychiatric, brain, and spine diseases; and radiology and nuclear medicine studies.

The JHCRN is a program of the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is a part of a national consortium aimed at transforming how clinical and translational research is conducted at academic health centers around the country.

Network researchers from participating hospitals will use a centralized data system to coordinate information from diverse information technology and electronic medical records sources. Clinical research methodologies, data management, research reporting documentation, patient consent forms, and quality- and safety-control criteria will be standardized. With this uniformity, network hospitals can better develop and coordinate their own clinical research activities or joint clinical trials with other JHCRN institutions.

Source: Dr. Charles Balch, Johns Hopkins Institute for Clinical and Translational Research
Writer: Walaika Haskins

TheUniversity of Maryland School of Medicine has received $12.3 million in National Institutes of Health (NIH) grants to renovate research laboratories of the University of Maryland Marlene and Stewart Greenebaum Cancer Center and to build core facilities � centralized areas of technology and expertise � that will provide key support services to cancer researchers. The funds are part of $1 billion in funding made available by the federal government through the American Recovery and Reinvestment Act for construction or renovation of research facilities.

The NIH's National Center for Research Resources (NCRR) has awarded a $5 million C06 construction grant to renovate laboratories on the eighth floor of the School of Medicine's Bressler Research Building at 655 W. Baltimore St. Another $7.3 million G20 Core Renovation, Repair and Improvement grant will be used to consolidate existing core laboratories and build new facilities on the sixth and seventh floors of the Bressler Building.

These new core laboratories will provide "shared services" to cancer researchers and other scientists at the University of Maryland School of Medicine and other professional schools at the University of Maryland, Baltimore. Many of these support services benefit the cancer center, which is part of the School of Medicine and the University of Maryland Medical Center.

"These NCRR grants will enable us to build new, modern laboratory facilities for our researchers that hopefully will pave the way for major breakthroughs in cancer research. We are continually expanding our research program, and constructing state-of-the-art laboratories is critical to that effort," says Kevin J. Cullen, M.D., director of the University of Maryland Marlene and Stewart Greenebaum Cancer Center and professor of medicine and director of the Program in Oncology at the University of Maryland School of Medicine.

"Our cancer center has been recognized by the National Cancer Institute for its scientific excellence, and our faculty members conduct some of the most innovative and promising cancer research in the nation. These new laboratories will not only facilitate this work but also will help us to recruit more top-tier scientists to our cancer center," says E. Albert Reece, M.D., Ph.D., M.B.A., acting president of the University of Maryland, Baltimore, and dean of the University of Maryland School of Medicine.

The newly renovated space will be used by individual molecular and structural biology researchers and will also house core labs for confocal microscopy, proteomics, flow cytometry, tissue-culturing and tissue-related services such as histology and immunohistochemistry, as well as the Genomics Core Facility, which provides cutting-edge genomic support for researchers.

The renovation on the eighth floor of the Bressler Building is scheduled to begin in November and will be completed in August 2011. The construction on the sixth and seven floors will begin upon completion of the eighth floor renovations and be finished by August 2012.


Source: University of Maryland Medical School
Writer: Walaika Haskins

The Maryland Biotechnology Center, the State of Maryland's portal to programs and resources intended to grow and strengthen the state's bioscience community, has awarded $270,000 through the Maryland Industrial Partnerships (MIPS) program to six biotechnology companies to their product development projects .

MIPS teams Maryland companies with faculty from the University System of Maryland to help the companies develop high technology, biotechnology, or technology-related agricultural products. Companies provide matching funds to help pay for the projects. All funding goes to participating faculty.

The Center recently signed off on initial funding for three projects. Each was in the second year of a two-year (phase 2) project. Three additional first-year projects were also made possible by freeing up MIPS funds to support them.

"As Maryland's resource center for growing and strengthening the state's bioscience community, one of the Maryland Biotechnology Center's charters outlined by Governor Martin O'Malley in his 2009 BioMaryland 2020 strategic plan is to provide funding to assist companies with late-stage commercialization objectives," says Judy Britz, the Center's executive director. "MIPS has a proven process for evaluating viable research projects and a strong history of successfully helping biotechnology companies develop commercial products, so by supporting MIPS, we are fulfilling part of our charter and are boosting key contributors to the growth of the state's bioscience cluster."

The phase 2 projects that the Center will directly support include Rockville-based Aparna Biosciences Corporation that has teamed with A. James Mixson, associate professor, University of Maryland, Baltimore to develop therapeutics to treat a variety of fungal infections; Encore Path Inc., based in Baltimore has, and Appa Anjanappa, professor, University of Maryland, Baltimore County, who are developing a new rehabilitative TREADTRAC Device to enable stroke patients to regain walking skills; and another Rockville-based company, VectorLogics Inc. and Vikram Vakharia, professor, University of Maryland Biotechnology Institute, who are working on a treatment for the hepatitis C virus that uses viral vectors to deliver therapeutic proteins.

MIPS was able to support three additional projects thanks to the Center funding, including, Rockville-based Celek Pharmaceuticals LLC and Susan Keay, professor, University of Baltimore, to evaluate the efficacy of a novel therapeutic for interstitial cystitis/painful bladder syndrome, a chronic and debilitating bladder disorder; Cellphire Inc., also in Rockville that has teamed with the University of Maryland Biotechnology Institute MDBioproSM (GMP Biomanufacturing Program) to establish a quality system and manufacturing processes for the current Good Manufacturing Practice (cGMP) production of the company's freeze-dried platelet products for both diagnostic and therapeutic indications; and College Park's Zymetis Inc. that is working with Robert M. Briber, professor, University of Maryland, College Park, in the development of low-cost solvent systems to reduce the crystallinity of native cellulose, reducing the need for enzymes in biomass digestion for the production of ethanol and other biofuels.

"MIPS has helped three of the most successful biotechnology companies in Maryland�MedImmune [part of AstraZeneca], Martek Biosciences, and Digene Corporation [now part of Qiagen]�develop products," says MIPS director Martha Connolly. "These companies have generated thousands of jobs, brought in millions in revenue and contributed tax dollars to the economy. The Maryland Biotechnology Center funding allows us to bolster what could be the leading biotechnology companies of tomorrow."

The Maryland Biotechnology Center contract with MIPS is for one year.

Source: The Maryland Biotechnology Center
Writer: Walaika Haskins

Zyngenia, a privately held biotherapeutics company headquartered in Montgomery County, was spurred by significant venture capital investments, led by a $10 million Series A investment from NEA in November 2009. The company has a current staff of 14 employees and plans to grow to at least 20 by the end of the year.

The strategic public/private partnership is a component of the County's recently unveiled Bioscience Strategy, which aims to enhance the environment for entrepreneurship and creation of new life science companies in the County by merging increased local venture capital funding with proven biotech entrepreneurs and seasoned industry executives.

Zyngenia uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into one protein (known as a Zybody™). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies. The company is focusing its early research and development in creating therapies for patients who have unmet medical needs in cancer and autoimmune diseases.

"Maryland's knowledge economy � one based on science, security, technology and healing � is fueled by innovative companies like Zyngenia," says Gov. Martin O'Malley. "By locating and expanding in Maryland, Zyngenia will have access to our vast community of biopharmaceutical companies, the nation's largest number of federal facilities and increased opportunities to attract venture capital funding."

Zyngenia's expansion and build-out is the latest in a series of other progressive, proactive initiatives by Montgomery County to grow the life sciences industry and bolster the local economy, including

• The new bioscience strategy recommendation of a first-of-its-kind local biotech tax credit to spur investments in biotech companies;

• Leggett's Smart Growth Initiative to create quality, high-paying jobs, and provide sufficient and affordable housing near mass transit by relocating certain County facilities, currently located on prime real estate near mass transit and within the Shady Grove Life Sciences Center, to make way for strategic commercial development; and,

• The forthcoming strategies from the County's Green Economy Task Force to further support and grow this evolving business sector.

Source: Montgomery County
Writer: Walaika Haskins

The Board -- comprised of the Governor, State Comptroller Peter Franchot, and State Treasurer Nancy K. Kopp -- approved the $6.45 million expenditure to begin the design phase of the new laboratory, which will help the state respond more rapidly to such public health events as newly emerging epidemics, foodborne outbreaks and incidents of bioterrorism. The laboratory is expected to have a price tag of $180 million, which will be funded by Lease Revenue Bonds issued by MEDCO and backed by the DHMH lease.

"The new public health lab will advance our goal of providing Maryland families the best public health service and protection that modern science and technology can offer," says Gov. O'Malley. "This state-of-the-art facility maximizes our abilities to protect the health and well-being of all Marylanders under a creative financing agreement that minimizes the cost to taxpayers."

As a member of the national Laboratory Response Network, the State laboratory acts as an early warning system for public health threats and shares this information with other state and federal agencies so that threats such as the drug resistance to H1N1 influenza can be identified, tracked, and quickly contained.

"As the H1N1 (Swine) flu experience clearly demonstrated, the public health laboratory is the backbone of Maryland's public health system," says John M. Colmers, DHMH Secretary. "The investment we are making today will provide Maryland families with decades of protection against disease and illness."

The structure will be a significantly more efficient building than the old facility that opened in 1974. The new laboratory will provide a 29 percent increase in useable space over the current facility, growing from 100,000 net assignable square feet to 129,000 net assignable square feet, while decreasing the actual gross square footage from the current 227,000 to an estimated 200,000 gross square feet. It will have 41 high-level biosafety laboratories, an infrastructure to support sophisticated instruments and equipment, and more sophisticated levels of security.

The new facility will be financed through the Maryland Economic Development Corporation (MEDCO), an instrumentality of the State created by the General Assembly to assist private and government agencies in expanding and modernizing existing enterprises in Maryland. Forest City-New East Baltimore Partnership, a nationally recognized developer of laboratory facilities and chosen by East Baltimore Development, Inc. as the developer for the Science and Technology Park at Johns Hopkins, will be the developer for the new public health laboratory.

Source: Board of Public Works
Writer: Walaika Haskins

The University of Maryland School of Medicine  has received a $30 million grant to create a center that will coordinate the research of national experts in stem cell research. The university's Michael L. Terrin, MD, CM MPH, professor of epidemiology and preventive medicine was pegged by the National Heart, Lung and Blood Institute (NHLBI) to lead the coordinating center, dubbed the NHLBI Profenitor Cell Biology Consortium, for a consortium of our nation's most prominent scientists in the field of stem cell research.

"This consortium was developed to bring together the best and brightest researchers from around the country, in the new and rapidly advancing field of stem and progenitor cell biology. They come from several specialties -- cardiology, hematology and pulmonary medicine. All are doing cutting edge research in this exciting new field," says Terrin.

Stem cells are uncommitted cells that can change into many types of mature functional cells and can divide indefinitely. Once stem cells start to commit to a cell type, they create progenitor cells. They are partially committed in terms of the types of cells they can become and how many times they can divide.

One major goal of this research consortium is to use these stem and progenitor cells as regenerative therapy to replace damaged tissues and organs.

The researchers will share their strategies and techniques to identify and characterize how these cells differentiate. Together they will address the challenges of discovering new potential therapies.

The NHLBI believes that by sharing information and working together across traditional boundaries, consortium members will advance the field of stem cell and progenitor cell biology at a faster pace and realize the potential for new clinical therapies that much sooner.

Terrin and his on campus colleagues  will organize the collaborative efforts of the nine different research hubs in the Consortium, dividing the responsibilities of the Administrative Coordinating Center into three areas: general administration; computer systems; and biological information science.

"Our team of nationally known experts, and the facilities at the University of Maryland School of Medicine, made our proposal to coordinate this consortium unique," Terrin says. "The resources here are wonderful. I know of no other university or medical school that I would rather have behind my efforts on behalf of this important project."

The research coordination team led by Terrin is composed of individuals who will assure that the information put in the system, as well as records of samples and tissues put into registries (both physical and virtual), will be maintained. They will also ensure that important information from sources outside the Consortium is continually updated.

In addition, Terrin's team will coordinate conference calls, meetings and funding for their research projects and help the investigators publicize their results of their research.

Source: University of Maryland, Baltimore
Writer: Walaika Haskins